![Dimitri Pournaras](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Dimitri Pournaras
Direttore/Membro del Consiglio presso Keyron Ltd.
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Giorgio Castagneto Gissey | M | 35 |
Keyron Ltd.
![]() Keyron Ltd. Medical SpecialtiesHealth Technology Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023. | 8 anni |
Marco Castagneto | M | - |
Keyron Ltd.
![]() Keyron Ltd. Medical SpecialtiesHealth Technology Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023. | 8 anni |
Carl D. Francis | M | - |
Keyron Ltd.
![]() Keyron Ltd. Medical SpecialtiesHealth Technology Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023. | 2 anni |
Nicholaas Verheem | M | 52 |
Keyron Ltd.
![]() Keyron Ltd. Medical SpecialtiesHealth Technology Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023. | - |
Carel Le Roux | M | 52 |
Keyron Ltd.
![]() Keyron Ltd. Medical SpecialtiesHealth Technology Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023. | - |
Francesco Rubino | M | 55 |
Keyron Ltd.
![]() Keyron Ltd. Medical SpecialtiesHealth Technology Keyron Ltd. is a preclinical-stage medical device and technology platform company based in Italy. The company is backed by multiple institutional investors based in the USA and EMEA. The company is based in Italy. The British company aims to provide a highly-effective treatment for metabolic diseases such as type-2 diabetes, NASH, and obesity. Keyron's patented Forepass™ is an innovative medical device that has already demonstrated a full reversal of insulin resistance in animal studies. The company has upcoming clinical trials in Europe and aims to carry out further clinical trials in the USA. Keyron's founders, directors, advisors, and investors include some of the most well-known and cited professors and KOLs worldwide in the metabolic diseases space. The company was founded in 2016 by Giorgio Castagneto Gissey and Marco Castagneto. Carl D. Francis has been the CEO of the company since 2023. | - |
Grafico relazionale
Relazione in diverse aziende
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Regno Unito | 6 | 100.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Dimitri Pournaras
- Contatti personali